Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-07-04 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, total amount spent, and compliance with relevant regulations. It does not contain financial statements or detailed financial analysis but reports on the company's own share transactions. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming this classification.
2022-07-04 Chinese
关于上海证券交易所对公司2021年年度报告监管工作函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed reply announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding a regulatory inquiry from the Shanghai Stock Exchange about the company's 2021 Annual Report. It discusses internal control deficiencies, related party transactions, financial data including cash balances, interest income, financing arrangements, and corrections to disclosures made in the 2021 Annual Report. The document includes extensive financial details and auditor opinions related to the annual report. The presence of detailed financial data, audit opinions, and corrections to the annual report disclosures indicates this is a regulatory response document related to the Annual Report, but it is not the Annual Report itself. It is a regulatory filing responding to a regulatory inquiry about the Annual Report. The document length is substantial (15,000 characters), and it contains substantive financial and audit information, not just an announcement of a report publication or a certification letter. Therefore, the best classification is Regulatory Filings (RNS), as it is a regulatory response document that does not fit the exact Annual Report (10-K) category but is related to regulatory compliance and disclosures.
2022-06-28 Chinese
天健会计师事务所关于灵康药业集团股份有限公司监管工作函专项说明
Regulatory Filings
2022-06-28 Chinese
2021年年度报告（修订版）
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, corporate governance, environmental and social responsibility, and financial statements. The document is lengthy (15,000 characters) and includes audited financial data, management analysis, and comprehensive company information. It also references the audit report by an accounting firm, but the document itself is the full annual report, not just the audit report or an announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-06-28 Chinese
2021年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the implementation of the 2021 annual equity distribution (dividend payment). It details the dividend per share, relevant dates for record, ex-dividend, and payment, the dividend distribution plan approved at the 2022 shareholders meeting, tax withholding details, and contact information for inquiries. The document is relatively short (3055 characters) and focuses solely on dividend distribution details without containing financial statements or comprehensive financial performance data. This matches the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and related shareholder details.
2022-06-28 Chinese
关于权益分派引起的“灵康转债”转股价格调整的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the adjustment of the conversion price of its convertible bonds due to equity distribution (cash dividends). It details the previous and adjusted conversion prices, the effective date of the adjustment, and the formulas used for the adjustment based on the company's profit distribution plans approved at annual general meetings. The document is a formal notice about a capital/financing update related to convertible bonds, specifically the adjustment of the conversion price, which affects the capital structure and financing terms. The document length is 1929 characters, which is relatively short but contains substantive information about the conversion price adjustment, not merely a report publication announcement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-06-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.